Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118

Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118–2125

Published:2013-11-13 Issue:12 Volume:36 Page:e213-e213
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Bjerre Knudsen Lotte¹,Nyborg Niels C. Berg¹,Svendsen Claus Bo²,Vrang Niels³,Moses Alan C.⁴

Affiliation:

1. Diabetes Research, Novo Nordisk A/S, Bagsværd, Denmark

2. Global Medical Affairs, Novo Nordisk A/S, Bagsværd, Denmark

3. Gubra Aps, Hoersholm, Denmark

4. Novo Nordisk, Princeton, New Jersey

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/36/12/e213/614910/e213.pdf

Reference7 articles.

1. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?;Butler;Diabetes Care,2013

2. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species;Nyborg;Diabetes,2012

3. The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis;Vrang;Am J Physiol Endocrinol Metab,2012

4. Choice of morphometric methods and consequences in the regulatory environment;Boyce;Toxicol Pathol,2010

5. Editorial: antibody validation requirements for articles published in endocrinology;Gore;Endocrinology,2013

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes;Advances in Therapy;2017-07-03

2. Studying Pancreatic Risks Caused by Incretin-Based Therapies;Journal of Diabetes Science and Technology;2014-05-12

3. Expression of the Glucagon Like Peptide-1 Receptor in Human Pancreas and Incretin Therapy;Endocrinology;2014-04-01

4. Response to Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118–2125;Diabetes Care;2013-11-13